Radioiodine therapy and Graves' ophthalmopathy

Journal of Nuclear Medicine

Volumn 49, Issue 6, 2008, Pages 923-930

  Sisson, James C ^a   Schipper, Matthew J ^a   Nelson, Christine C ^b   Freitas, John E ^a   Frueh, Bartley R ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Clinical activity score; Graves' ophthalmopathy; Quality of life questionnaire; Radioiodine therapy

Indexed keywords

RADIOACTIVE IODINE; THYROID STIMULATING IMMUNOGLOBULIN; THYROXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; FEMALE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SYMPTOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 44849108985     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.049437     Document Type: Article

References (21)

1. Tallstedt L, Lundall G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med. 1992;326:1733-1738.
2. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998;338:73-78.
3. Kung AWC, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab. 1994;79:542-546.
4. Manso PG, Furlanetto RP, Wolosker AMB, Paiva ER, de Abreu MT, Maciel RMB. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism. Thyroid. 1998;8:49-52.
5. Bonnema SJ, Bartalena L, Toft AD, Hegedis L. Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goiters. Eur J Endocrinol. 2002;147:1-11.
6. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab. 2005;90:5321-5323.
7. Hamilton RD, Mayberry WE, McConahey WM, Hanson KC. Ophthalmopathy of Graves' disease, a comparison between patients treated surgically and patients treated with radioiodide. Mayo Clin Proc. 1967;42:812-818.
8. Barbosa J, Wong E, Doe RP. Ophthalmopathy of Graves' disease. Arch Intern Med. 1972;130:111-113.
9. Gwinup G, Elias AN, Ascher MS. Effect on exophthalmos of various methods of treatment of Graves' disease. JAMA. 1982;247:2135-2138.
10. Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med. 1989;87:70-73.
11. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab. 1990;70:1518-1524.
12. 131I therapy of the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2002;87:1073-1077.
13. Mourits MPh, Prummel MF, Wiersinga WM, Koornneef L. Clincial activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9-14.
14. Frueh BR. Graves' eye disease: orbital compliance and other physical measurements. Trans Am Ophthalmol Soc. 1984;82:492-598.
15. Frueh BR, Musch DC, Garber FW. Exophthalmometer readings in patients with Graves' eye disease. Ophthalmic Surg. 1986;17:37-40.
16. Migliori ME, Gladstone GJ. Determination of the normal range of exophthalmetric values for black and white adults. Am J Ophthalmol. 1984;98:438-442.
17. Tsai CC, Kau HC, Kao SC, Hsu WM. Exophthalmos of patients with Graves' disease in Chinese of Taiwan. Eye. 2006;20:569-573.
18. Vestergaard P. Smoking and thyroid disorders: a meta-analysis. Eur J Endocrinol. 2002;146:153-161.
19. Centers for Disease Control and Prevention. State-specific prevalence of cigarette smoking and quitting among adults: United States, 2004. Morb Mortal Wkly Rep. 2005;54:1124-1127.
20. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994;130:494-497.
21. Terwee CB, Gerding MN, Dekker FW, Prummel MF, van der Pol JP, Wiersinga WM. Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy. J Clin Epidemiol. 1999;52875-884.